Stifel lowers Abeona Therapeutics stock price target on launch delay

Stifel lowered its price target for Abeona Therapeutics (ABEO) to $19 from $20, while reiterating a Buy rating, following a three-month delay in the commercial launch of its Zevaskyn product due to a sterility assay issue, which led to a reduced Q4 2025 revenue estimate. Despite this near-term setback, Stifel expressed increased confidence in FY2026 and beyond, citing strong demand signals, significant progress in reimbursement, and the company's robust liquidity. This outlook is further supported by Abeona's recent Q3 2025 earnings beat, where it exceeded EPS estimates by 62.96% through strategic cost management, suggesting potential value despite recent stock declines.

Analysis

Stifel has adjusted its price target for Abeona Therapeutics (ABEO) to $19.00 from $20.00, while maintaining a Buy rating, following a three-month delay in the commercial launch of its Zevaskyn product. This delay stems from an FDA-mandated sterility assay issue that produced a false positive, leading Stifel to reduce its fourth-quarter 2025 revenue estimate to $8 million, reflecting expectations for only three patient treatments. Further uncertainty surrounds revenue recognition due to a mid-December manufacturing shutdown for quality control.

Despite these near-term operational challenges, Stifel expressed increased confidence in Zevaskyn's fiscal year 2026 and beyond estimates, citing management's commentary on strong demand trends, including 12 patient start forms and increasing referrals. Abeona has also made significant progress on reimbursement, securing a permanent J-code, coverage for approximately 80% of commercial lives, and inclusion in all state Medicaid programs, supporting its path to sustainable profitability.

Financially, Abeona demonstrates strong liquidity with a current ratio of 6.73 and holds more cash than debt. The company recently exceeded Q3 2025 EPS expectations, reporting -$0.10 against a projected -$0.27, attributed to effective cost management. With net income expected to grow this year and a FY2025 EPS forecast of $0.12, coupled with an oversold RSI and a P/E ratio of 5.11, the stock presents potential value despite trading slightly above its Fair Value.

Key Decisions for Investors

• Investors should assess the current stock price, which is trading at $5.07 and is oversold, as a potential entry point given the maintained Buy rating and long-term positive outlook.
• Monitor the successful resolution of the sterility assay issue and the subsequent ramp-up of Zevaskyn treatments, as operational execution and revenue recognition timing will be critical catalysts.
• Focus on Abeona's fiscal year 2026 guidance and beyond, given the strong demand signals and significant reimbursement progress, which underpin the company's path to sustainable profitability.